OneSource Bengaluru Sterile Plant Gets USFDA VAI Status
OneSource Specialty Pharma has received a USFDA EIR with VAI classification for its Bengaluru Sterile Product Division, closing the June 2026 inspection.
OneSource Specialty Pharma has received a USFDA EIR with VAI classification for its Bengaluru Sterile Product Division, closing the June 2026 inspection.
Senores Pharmaceuticals will expand capacity at its US subsidiary Havix from 1.2 billion to 2 billion units a year and at Apnar Pharma in India from 0.5 billion to 1.2 billion units, and add a 2.7 million-unit prefilled syringe line at Ratnatris, for an estimated ₹43 crore by March 2027.
Theon Group has bought Maneesh Pharma’s Unit VI in Baddi, Himachal Pradesh, through a slump sale. Renamed Zoevita Lifesciences, the WHO-GMP oral-solids plant can make 3 billion tablets, 150 million capsules and 30 million sachets a year, with oral liquids planned.
Sudeep Pharma has received Gujarat FDA approval to begin manufacturing at its new 51,200 MT greenfield facility at Nandesari, with commercial supplies of excipients and specialty ingredients expected from H2 FY27 after customer qualification.
Morepen Laboratories reported Q2 FY27 revenue of ₹755 crore, up 81%, and EBITDA of ₹132 crore, up 273%, as its CDMO business hit commercial scale, exports more than doubled and it filed its first US ANDA.
Hyderabad: Reinforcing its status as India’s pharmaceutical capital, Hyderabad is rapidly emerging as a global hub for healthcare innovation, pharmaceutical […]